The pharma is headquartered in the US, with research sites also in Boston/Worcester, Bay area and Germany. The firm forms partnerships with development stage biotech companies via a variety of structures, including strategic venture investments, in-licensing, collaborations, and M&A. The company looks globally for opportunities.
The pharma focuses on transformative therapeutic assets in oncology (including immuno-oncology), immunology and autoimmune diseases, and neurodegenerative diseases (priority areas being Alzheimer’s disease and Parkinson’s disease) & psychiatric diseases (including mood disorders). The firm is also interested in therapeutics addressing fibrotic diseases and some infectious diseases such as HBV. The pharma is open to biologics and cell / gene therapies in addition to small molecules. The pharma will consider assets at any stage of development, but is particularly interested in outreach from companies developing early stage assets and technologies.
If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.
Leave a Reply